A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

PHASE3CompletedINTERVENTIONAL
Enrollment

321

Participants

Timeline

Start Date

August 12, 2020

Primary Completion Date

May 22, 2024

Study Completion Date

June 4, 2024

Conditions
Systemic Lupus Erythematosus
Interventions
DRUG

DZP

Subjects will receive dapirolizumab pegol at prespecified time-points.

OTHER

Placebo

Subjects will receive placebo at prespecified time-points.

Trial Locations (177)

10021

Sl0043 50077, New York

10032

Sl0043 50334, New York

11021

Sl0043 50266, Great Neck

11030

Sl0043 50264, Manhasset

11201

Sl0043 50010, Brooklyn

13210

Sl0043 50241, Syracuse

13617

Sl0043 50366, Canton

15232

Sl0043 50365, Pittsburgh

16635

Sl0043 50020, Duncansville

17033

Sl0043 50147, Hershey

19107

Sl0043 50364, Philadelphia

20060

Sl0043 50341, Washington D.C.

21502

Sl0043 50288, Cumberland

21740

Sl0043 50015, Hagerstown

25801

Sl0043 50050, Beckley

26505

Sl0043 50321, Morgantown

28211

Sl0043 50238, Charlotte

30303

Sl0043 50368, Atlanta

30309

Sl0043 50382, Atlanta

32174

Sl0043 50059, Ormond Beach

32610

Sl0043 50362, Gainesville

33136

Sl0043 50122, Miami

33324

Sl0043 50324, Plantation

33511

Sl0043 50239, Brandon

33606

Sl0043 50329, Tampa

33613

Sl0043 50283, Tampa

35205

Sl0043 50140, Birmingham

38305

Sl0043 50001, Jackson

45242

Sl0043 50330, Cincinnati

48201

Sl0043 50219, Detroit

48439

Sl0043 50333, Grand Blanc

60076

Sl0043 50360, Skokie

60612

Sl0043 50310, Chicago

70605

Sl0043 50285, Lake Charles

73104

Sl0043 50262, Oklahoma City

75150

Sl0043 50036, Mesquite

75231

Sl0043 50057, Dallas

75390

Sl0043 50304, Dallas

76034

Sl0043 50418, Colleyville

77401

Sl0043 50338, Bellaire

79124

Sl0043 50263, Amarillo

80230

Sl0043 50339, Denver

83404

Sl0043 50240, Idaho Falls

85032

Sl0043 50052, Phoenix

85704

Sl0043 50328, Tucson

89128

Sl0043 50273, Las Vegas

90022

Sl0043 50258, Los Angeles

90211

Sl0043 50383, Beverly Hills

92037

Sl0043 50257, La Jolla

92064

Sl0043 50331, Poway

92108

Sl0043 50377, San Diego

92354

Sl0043 50378, Loma Linda

92868

Sl0043 50340, Orange

94578

Sl0043 50316, San Leandro

98195

Sl0043 50267, Seattle

99204

Sl0043 50061, Spokane

90623-1730

Sl0043 50275, La Palma

06519

Sl0043 50367, New Haven

42240-1746

Sl0043 50474, Hopkinsville

27157-1010

Sl0043 50179, Winston-Salem

Unknown

Sl0043 60002, Capital Federal

Sl0043 60001, Ciudad Autonoma de Buenos AIRE

Sl0043 60029, Mendoza

Sl0043 60003, Quilmes

Sl0043 60022, Quilmes

Sl0043 60011, San Juan

Sl0043 60014, San Miguel de Tucumán

Sl0043 30020, Parkville

Sl0043 30025, St Albans

Sl0043 40388, Graz

Sl0043 40387, Vienna

Sl0043 40123, Brussels

Sl0043 40060, Liège

Sl0043 40006, Plovdiv

Sl0043 40189, Plovdiv

Sl0043 40522, Plovdiv

Sl0043 40380, Sofia

Sl0043 50374, Calgary

Sl0043 50337, Edmonton

Sl0043 50259, Rimouski

Sl0043 50045, Toronto

Sl0043 50044, Trois-Rivières

Sl0043 60021, Providencia, Santiago

Sl0043 60015, Santiago

Sl0043 60018, Santiago

Sl0043 60030, Santiago

Sl0043 60013, Barranquilla

Sl0043 60019, Barranquilla

Sl0043 60006, Bogotá

Sl0043 60027, Bogotá

Sl0043 60016, Bucaramanga

Sl0043 60007, Chía

Sl0043 60028, Medellín

Sl0043 60031, Montería

Sl0043 40066, Prague

Sl0043 40489, Odense

Sl0043 40506, Montpellier

Sl0043 40505, Paris

Sl0043 40386, Cologne

Sl0043 40322, Dessau

Sl0043 40356, Dresden

Sl0043 40072, Freiburg im Breisgau

Sl0043 40024, Hanover

Sl0043 40027, Herne

Sl0043 40078, Leipzig

Sl0043 40402, Tübingen

Sl0043 40378, Athens

Sl0043 40377, Crete

Sl0043 40501, Haidari - Athens

Sl0043 40507, Larissa

Sl0043 40375, Thessaloniki

Sl0043 40412, Budapest

Sl0043 40411, Debrecen

Sl0043 40413, Gyula

Sl0043 40031, Szeged

Sl0043 40499, Székesfehérvár

Sl0043 40084, Catania

Sl0043 40472, Ferrara

Sl0043 40514, Genova

Sl0043 40291, Milan

Sl0043 40448, Milan

Sl0043 40471, Milan

Sl0043 40509, Padua

Sl0043 40148, Roma

Sl0043 40492, Rozzano

Sl0043 50317, Chihuahua City

Sl0043 50250, Cuernavaca

Sl0043 50249, Guadalajara

Sl0043 50271, León

Sl0043 50252, Mérida

Sl0043 50251, Monterrey

Sl0043 60026, Arequipa

Sl0043 60008, Lima

Sl0043 60009, Lima

Sl0043 60023, Lima

Sl0043 20110, Angeles

Sl0043 20182, Davao City

Sl0043 20181, Makati

Sl0043 20111, Manila

Sl0043 40482, Bialystok

Sl0043 40119, Bydgoszcz

Sl0043 40398, Katowice

Sl0043 40490, Krakow

Sl0043 40502, Krakow

Sl0043 40037, Lublin

Sl0043 40151, Lublin

Sl0043 40483, Nadarzyn

Sl0043 40044, Poznan

Sl0043 40090, Poznan

Sl0043 40097, Warsaw

Sl0043 40098, Warsaw

Sl0043 40394, Warsaw

Sl0043 40397, Wroclaw

Sl0043 40481, Wroclaw

Sl0043 40383, Bucharest

Sl0043 40464, Bucharest

Sl0043 40382, Galati

Sl0043 40393, Belgrade

Sl0043 40461, Belgrade

Sl0043 40466, Kragujevac

Sl0043 40392, Novi Sad

Sl0043 20141, Busan

Sl0043 20106, Daejeon

Sl0043 20108, Incheon

Sl0043 20104, Seoul

Sl0043 40045, A Coruña

Sl0043 40160, Barcelona

Sl0043 40341, Málaga

Sl0043 40521, Mérida

Sl0043 40101, Sabadell

Sl0043 40400, Seville

Sl0043 40099, Vigo

Sl0043 20113, Taichung

Sl0043 20142, Taichung

Sl0043 20095, Taipei

Sl0043 20099, Taipei

Sl0043 20082, Taoyuan

All Listed Sponsors
lead

UCB Biopharma SRL

INDUSTRY

NCT04294667 - A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus | Biotech Hunter | Biotech Hunter